cas 45214-91-3|| where to buy (2S)-5-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid

Nom du produit:(2S)-5-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid

IUPAC Name:(2S)-2-{[(tert-butoxy)carbonyl]amino}-5-methoxy-5-oxopentanoic acid

Unité d'emballage	Stock disponible	Prix($)
CM101954-500g	in stock	œȤŸ
CM101954-1000g	in stock	ǆƐş

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 45214-91-3 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:45214-91-3; Formule moléculaire:C11H19NO6; Point de fusion:-; Code SMILES:O=C(O)[C@@H](NC(OC(C)(C)C)=O)CCC(OC)=O; Densité:

: Numéro de catalogue:CM101954; Poids moléculaire:261.27; Point d'ébullition:428.4°C at 760 mmHg; N° Mdl:MFCD00190794; Stockage:Store at room temperature.

: Amino Acids and Peptides; Amino acids are organic compounds containing a basic amino group and an acidic carboxyl group. Because amino acids contain both amino and carboxyl groups, they can be polymerized in an end-to-end manner, removing a molecule of water to form a covalent amide bond or peptide bond. Many amino acids are linked together end to end to form a polypeptide. Amino acids and peptides are important components in the fields of medicine and life sciences.; amino acids wholesale; if you are finding amino acids wholesaler in china, we will be your best choose! We have our own factory, so we can give you a cheap price!

: Bomedemstat; Merck recently announces the initiation of the pivotal Phase 3 randomized MK-3543-006 clinical trial of Bomedemstat for Essential Thrombocythemia (ET). Lysine-specific demethylase 1 (LSD1) is critical for the regulation of hematopoietic stem and progenitor cells. Bomedemstat is an investigational small molecule irreversible inhibitor of LSD1 by suppressing progenitor cells during blood cell maturation. It is generally well tolerated in ET patients and demonstrates significant clinical activity as a monotherapy.
Bomedemstat has been granted Orphan Drug and Fast Track Designation for the treatment of ET and myelofibrosis (MF) by the U.S. FDA.